Harmony Biosciences reports Q3 revenue of $239M, raises FY25 revenue guidance

* Harmony Biosciences (NASDAQ:HRMY [https://seekingalpha.com/symbol/HRMY]) on Thursday reported net revenue of ~$239M in Q3 2025, vs consensus of $220.04M, representing 29% year-over-year revenue growth.
* These results were driven by the highest ever quarterly increase in average number of patients of about 500 for the quarter, reaching 8,100 average patients in Q3 2025, the company said.
* Harmony increased its 2025 revenue guidance to $845-$865 million from the previous range of $820-$860 million, vs consensus of $841.56M.
* The company will report full Q3 2025 earnings and host a conference call on November 4th.
* HRMY +6.59% premarket to $28.
* Source: Press Release [https://seekingalpha.com/pr/20277202-harmony-biosciences-preannounces-strong-q3-2025-wakix-performance-raises-2025-revenue]

MORE ON HARMONY BIOSCIENCES HOLDINGS, INC.

* Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade [https://seekingalpha.com/article/4825970-harmony-biosciences-cannabinoid-fragile-x-fail-merits-rating-downgrade]
* Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug [https://seekingalpha.com/article/4815392-harmony-biosciences-reiterating-buy-ahead-of-data-catalyst-cannabinoid-drug]
* Harmony Bio slips on late-stage trial setback for Fragile X syndrome therapy [https://seekingalpha.com/news/4498345-harmony-bio-posts-trial-setback-fragile-x-therapy]
* Harmony targets $1B+ WAKIX sales in narcolepsy as late-stage pipeline advances [https://seekingalpha.com/news/4479056-harmony-targets-1b-wakix-sales-in-narcolepsy-as-late-stage-pipeline-advances]